ADCT — ADC Therapeutics SA Income Statement
0.000.00%
Last trade - 00:00
- $389.54m
- $527.24m
- $69.56m
- 10
- 11
- 97
- 33
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 20-F | 20-F | 10-K | 10-K |
Standards: | IFRS | IFRS | IFRS | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2.34 | 0 | 33.9 | 210 | 69.6 |
Cost of Revenue | |||||
Gross Profit | — | — | 32.5 | 207 | 67 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 122 | 219 | 296 | 375 | 236 |
Operating Profit | -119 | -219 | -262 | -165 | -166 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -116 | -246 | -252 | -147 | -195 |
Provision for Income Taxes | |||||
Net Income After Taxes | -116 | -246 | -230 | -147 | -235 |
Equity in Affiliates | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -116 | -246 | -230 | -157 | -240 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -116 | -246 | -230 | -157 | -240 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.52 | -3.21 | -3.07 | -1.66 | -2.94 |
Dividends per Share |